IP Library Granted Patent US 11,033,563
Granted Patent B2
US 11,033,563 · App. 16/422,079 · Granted Jun 15, 2021

Use of lactulose in the treatment of autism

Inventors: Joan M. Fallon (White Plains, NY); Richard Feltenstein (New Rochelle, NY)
Assignee: CUREMARK, LLC
A61K31/7016A61K31/045A61K31/047A61K31/7012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,563
App. No.
16/422,079
Granted
Jun 15, 2021
Kind
B2
Abstract

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Claims (16)

1. A method of increasing fermentation of bacteria in a colon in a subject diagnosed with Autism, the method comprising administering an effective amount of lactulose and mannitol to the subject, wherein administration of lactulose and mannitol to the subject increases fermentation of bacteria in the colon of the subject.

2. The method of claim 1 , wherein the effective amount of lactulose comprises about 0.4 g/kg lactulose per dose.

3. The method of claim 1 , wherein the effective amount of lactulose comprises about 0.3 g/kg lactulose per dose.

4. The method of claim 1 , wherein the effective amount of mannitol comprises about 0.1 g/kg mannitol per dose.

5. The method of claim 1 , wherein the effective amount of lactulose is administered to the subject approximately two to five times per day.

6. The method of claim 1 , wherein administration of lactulose increases the fermentation by lactobacilli, bifidobacteria, or a combination of lactobacilli and bifidobacteria in the subject.

7. The method of claim 1 , wherein the effective amount of lactulose is administered to the subject in a form selected from the group consisting of a powder, liquid solution, syrup, and a combination thereof.

8. The method of claim 1 , wherein the method does not include administration of an antibiotic to the subject.

9. The method of claim 1 , wherein administration of lactulose to the subject decreases a level of ammonia in the blood of the subject.

10. The method of claim 1 , wherein administration of lactulose to the subject decreases a level of ammonia in the gastrointestinal tract of the subject.

11. The method of claim 1 , wherein administration of lactulose to the subject decreases a level of ammonia in the nervous system of the subject.

12. The method of claim 1 , wherein increased fermentation of bacteria reduces neurotoxicity in the subject.

13. The method of claim 1 , wherein administration of lactulose to the subject reverses ammonia poisoning caused by administration of antibiotics that leave a residue in the gastrointestinal tract.

14. The method of claim 1 , wherein administration of lactulose to the subject lowers the colonic pH of the subject.

15. A method for increasing fermentation of bacteria in a colon in a subject diagnosed with Autism, the method comprising administering an effective amount of lactulose and mannitol to the subject, wherein the effective amount of lactulose is administered to the subject approximately two to five times per day.

16. A method for increasing fermentation of bacteria in a colon in a subject diagnosed with Autism, the method comprising administering an effective amount of lactulose and mannitol to the subject, wherein administration of lactulose to the subject reverses ammonia poisoning caused by administration of antibiotics that leave a residue in the gastrointestinal tract.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2019
From: FALLON, JOAN M.; FELTENSTEIN, RICHARD
To: CUREMARK, LLC
Reel/Frame 049736/0261 →
Continuity (6)
Continuation 15089842 · Apr 4, 2016
Continuation 14087930 · Nov 22, 2013
Continuation 13204881 · Aug 8, 2011
Division 12049613 · Mar 17, 2008
Division 11468379 · Aug 30, 2006
Related Publication 20190275066A1 · Sep 12, 2019
Cited By (1)
US 12,485,094